Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL511 in Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
NCT06617897Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Oct 2024
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Fibrinogen human in acquired fibrinogen deficiency (AFD) (2 arms), sponsored by CSL Limited. Primary endpoint: Percentage of participants with overall hemostatic success. Started Oct 2024; status: recruiting.
02
Drugs
Fibrinogen human
03
Conditions
acquired fibrinogen deficiency (AFD)
Beyond the preview
Go deeper on NCT06617897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617897.